Kör D, Şeker-Yılmaz B, Bulut FD, Kılavuz S, Öktem M, Ceylaner S, Yıldızdaş D, Önenli-Mungan N. Clinical features of 27 Turkish Propionic acidemia patients with 12 novel mutations. Turk J Pediatr 2019; 61: 330-336. Propionic acidemia (PA) is an inherited metabolic disease caused by the deficiency of one of the four biotin-dependent enzymes propionyl-CoA carboxylase (PCC), and is characterized by coma and death in unrecognized patients, additionally late diagnosis leads to severe developmental delay and neurological sequels. Manifestations of PA over time can include growth impairment, intellectual disability, seizures, basal ganglia lesions, pancreatitis, and cardiomyopathy. Other rarely reported complications include optic atrophy, hearing loss, premature ovarian insufficiency, and chronic renal failure. Mutations in PCCA-PCCB genes cause the clinically heterogeneous disease of PA. In this study, we investigate the mutation spectrum of PCCA-PCCB genes and phenotypic features of 27 Turkish patients with PA from the South and Southeast parts of Turkey. We report 12 novel PA mutations, five affecting the PCCA gene and 7 affecting the PCCB gene.
Propionic acidemia (PA; MIM# 232000 and 232050) is an autosomal recessive inherited metabolic disorder caused by the deficiency of the mitochondrial biotin-dependent enzyme propionyl-CoA carboxylase (PCC), which catalyzes the conversion of propionyl coenzyme A (propionyl-CoA) to methylmalonylcoenzyme A (methylmalonyl-CoA). 1 PCC is essential for the catabolism of the branchedchain amino acids, odd-numbered fatty acids, cholesterol, and other metabolites. 2 The PCC holoenzyme is a dodecamer composed of an equal number of alpha and beta subunits. 3 The alpha subunit is encoded by the PCCA gene (chromosome 13q32, MIM#232000). The beta subunit is encoded by the PCCB gene (chromosome 3q13.3-q22, MIM#232050). 4 Mutations in either the PCCA or PCCB gene cause PCC deficiency. To date, 149 mutations in the PCCA gene and 131 in the PCCB gene have been collected in the Human Genome Mutation Database (HGMD ® Professional 2018.4). The PCC deficiency results in increased amounts of diagnostic intermediates of methylcitrate, 3-hydroxypropionate and propionylcarnitine in urine and plasma. 5 The clinical features of PA are highly heterogeneous. Affected patients most commonly present in the neonatal period. Vomiting, refusal of feeding, dehydration, lethargy, hypotonia, seizures, metabolic acidosis, hyperammonemia, and hypoglycemia are the prominent signs and symptoms of the disease. The clinical picture can quickly progress to coma and death in unrecognized patients, however late diagnosis leads to severe developmental delay and neurological sequelae. [6] [7] Additionally, chronic complications of PA may affect the whole body with neurological, cardiologic, hematologic, immunologic, endocrine, and gastrointestinal manifestations. 8 Therefore, early diagnosis and proper treatment are crucial. The main principles of PA treatment consist of proteinrestricted diet, carnitine supplementation, and prevention of catabolism in fasting situations.
In this study, we investigate the mutation spectrum of PCCA-PCCB genes and phenotypic features of 27 Turkish patients with PA from the South and Southeast parts of the country.
Material and Methods
We conducted a retrospective study of patients with PA at Çukurova University Faculty of Medicine, Department of Pediatric Metabolism and Nutrition. Twenty-seven patients with PA, who came from 21 unrelated families were included in this study. All the patients were diagnosed with the clinical features confirmed by urine organic acid analysis and gas chromatography-mass spectrometry (GC-MS) and not through a neonatal screening program (NSP). Clinical diagnosis was confirmed by PCCA and PCCB genes analysis. PCCA and PCCB genes sequence analysis was performed by using MiSeq next generation sequencing (NGS) platform (Illumina, San Diego, CA, USA). The Ethics Committee of the Cukurova University Faculty of Medicine approved this study (Approval number: 2017/85-52).
Mutation Analyses of PCCA and PCCB genes
Genomic DNA was extracted according to the manufacturer's standard procedure using the Anatolia Magnesia Blood Kit (Anatolia Geneworks, Turkey). All coding exons and their flanking splice site junctions were amplified using PCR primers, designed with PRIMER © - Mutations were screened in the literature. In silico analysis of the variations was done with Varsome software. Variants were also checked in 2500 exome sequencing data of our patients. This data is of patients applied to our Intergen Genetics Center for diagnostic purposes. HiSeqControl Software, CLC Bio Genomics Workbench, SeattleSeq Annotation was used for analysis.
Results
The frequently observed initial symptoms, signs and laboratory findings that lead to PA diagnosis were feeding difficulties (48.1%), asymptomatic with family history of PA (40.7%), vomiting (37%), tachypnea (37%), hypotonia (26%), lethargy (14.8%), seizures (11.1%), pancytopenia (7.4%), hypoglycemia (3.7%), and feeding refusal (3.7%). Patients' characteristics and clinical data are presented in Table 1 . In this study, most of the parents (96.3%) were consanguineous. Positive family history rate was 19/27 (70.4%). The current age of the patients ranged from 0.3-35.6 years. The age at onset of symptoms was from birth to 18 months (median:3 days, mean: 40.44±108.8), and the age of diagnosis ranged from the prenatal period to 10.5 years (median: 35.5 days, mean: 295.12±828.3 days). Nineteen patients became symptomatic within the first 10 days of life, 4 patients within 10-30 days of life, and the remaining 4 patients in the second month of life. Twentytwo patients had severe clinical phenotype, and the remaining five patients had milder phenotype. Seventeen patients (63%) were still alive, while 10 patients had died during an acute metabolic crisis. Metabolic acidosis was reported in 23 patients, and 16 out of 23 patients had hyperammonemia (Table  I) . Hyperammonemia was seen as high as in urea cycle defects. The highest concentration found in our study cohort was >1000 µmol/L. Pancytopenia was found in six patients and creatine kinase levels were increased in six patients (Table II) . A total of 12 different PCCB and 8 different PCCA gene mutations were identified (Table III) , of which 12 were novel. Only one same mutant allele was identified in two unrelated patients (patient [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Different mutations were detected in all other patients. No genotype-phenotype correlations were found. within the first ten days of life. Other studies also reported early occurrence of symptoms as 71-92%. [9] [10] [11] The most common initial symptoms of PA patients were vomiting, feeding difficulties, feeding refusal, and failure to thrive. In our patient group also feeding problems, vomiting and feeding refusal were the most frequent manifestations (70%), especially when compared with neurological signs. Although in some series, gastroenterological problems are more prominent at admission 9,12-13 , most 13 . In another study, clinical manifestations were reported to occur in the first week in 84% and the first 2 weeks of life in 92% of patients. 11 In this study, median age at diagnosis is later than the reported in the literature because the time interval between the onset of symptoms and the admission to hospital is longer in our patient population.
The mortality rate was found to be 37% in our study. In a similar study 42 early-onset PA patients were included and mortality rate was reported to be 33%. 9 In another study, mortality rate was reported as 90% up to 6 years. 16 Whereas, in a study, involving patients diagnosed with NSP, mortality rate was reported as 8%. 13 This clearly shows that early diagnosis of PA through NSP is associated with a tendency toward lower mortality rates.
In our study, we identified 12 different mutations in the PCCB gene and 8 different mutations in the PCCA gene. Further, we identified seven mutations in PCCB gene and five mutations in PCCA gene, that had not previously been published. Our study shows the predominance of PCCB gene mutations, in similarity with other studies, although we have a relatively small patient cohort. 12, [17] [18] [19] On the contrary, some other studies showed a higher percentage of PCCA gene mutations. [20] [21] [22] No single common mutation was identified in both genes. A large number of novel mutations was detected in our study (60%). The variety of mutations may suggest the highly heterogeneous nature of genotype of PA in Turkey. The study included patients from the south and southeast parts of Turkey. This geographical region has the highest rates of parental consanguinity in Turkey. Patients included in this study were from different socioeconomic status and ethnicities. So, this cohort may not reflect the entire country therefore this may be the limitation of this study. Further multicentre, longitudinal studies are needed to better elucidate the clinical spectrum of the disease. Lack of NSP and delay in diagnosis seem to be major factors associated with poor outcomes and increased mortality of children in the present study.
In this study, we report the clinical and molecular characteristics of 27 Turkish patients which provides additional knowledge to the genotype and phenotype of PA. Our data suggest that PCCA and PCCB mutations in Turkish populations are distinct from other populations. Genetic heterogeneity was observed in our cohort in spite of the high rate of consanguineous marriages in Turkey, which are considered to be an important factor contributing to the higher incidences of autosomal recessive hereditary diseases. In addition, seven novel mutations in the PCCB gene and five novel mutations in the PCCA gene were identified, and therefore expand the mutational spectrum of these PCCA-PCCB genes.
